Notice of Intent to Publish a Funding Opportunity Announcement for Trailblazer Award for New and Early-Stage Investigators (R21 Clinical Trial Optional)
Last verified by NonDilute: 2026-06-08. Official notice and agency instructions control.
If you're a junior researcher with a bold clinical hypothesis and need seed funding to generate preliminary data, watch for this R21 announcement.
Report stale or inaccurate summary
What this is
This is a Notice of Intent (NOI) for an upcoming NIH funding opportunity targeting early-career researchers conducting novel clinical science. The R21 mechanism funds exploratory, proof-of-concept research typically in the $275K–$375K range over 2 years. Clinical trial involvement is optional, making it flexible for researchers at the hypothesis-generation or early-validation stage. However, critical details—exact budget, eligibility criteria, and application deadlines—are not yet published; this is advance notice only.
Who can apply
Intended for new and early-stage clinical investigators, typically at academic institutions or research organizations. Exact applicant type eligibility (individual, institution, non-profit status) will be clarified in the full funding announcement.
Topics: early-stage investigators · R21 grant · clinical research · NIH funding · trailblazer award · new investigator
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.